Isaac Erickson joined DiscGenics to manage the regulatory efforts in Japan leading to the successful acceptance of a Clinical Trial Notification (CTN). He also developed and directs the logistics network in support of both domestic and foreign clinical trials. In addition, Isaac is leading the process engineering group in assessing and implementing technology for successful transfer to DiscGenics’ new manufacturing site. Previous to DiscGenics, Isaac cultivated extensive experience in using sodium hyaluronate hydrogels for tissue engineering and stem cell delivery at both the University of Pennsylvania and at BioTime. Altogether, Isaac has spent nearly 15 years in the fields of sodium hyaluronate and regenerative medicine producing academic publications, developing new products, supporting clinical trials, and establishing new technology.